Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

F0260000

Fluphenazine decanoate

European Pharmacopoeia (EP) Reference Standard

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C32H44F3N3O2S
Número de CAS:
5002-47-1
Peso molecular:
591.77
EC Number:
225-672-4
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fluphenazine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

InChI key

VIQCGTZFEYDQMR-UHFFFAOYSA-N

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluphenazine decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Referencia del producto
Descripción
Precios

Y0000009

Fluphenazine enantate, European Pharmacopoeia (EP) Reference Standard

Y0000298

Fluphenazine octanoate, European Pharmacopoeia (EP) Reference Standard

Y0000299

Fluphenazine sulfoxide, European Pharmacopoeia (EP) Reference Standard

Y0000708

Fluphenazine impurity mixture, European Pharmacopoeia (EP) Reference Standard

F0280000

Fluphenazine dihydrochloride, European Pharmacopoeia (EP) Reference Standard

1282004

Fluphenazine hydrochloride, United States Pharmacopeia (USP) Reference Standard

1280803

Fluphenazine decanoate dihydrochloride, United States Pharmacopeia (USP) Reference Standard

1281001

Fluphenazine enanthate dihydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1792

Fluphenazine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP167

Fluphenazine hydrochloride, British Pharmacopoeia (BP) Reference Standard

1282026

Fluphenazine Related Compound B, United States Pharmacopeia (USP) Reference Standard

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

hcodes

H300,H361

Hazard Classifications

Acute Tox. 2 Oral - Repr. 2

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ayman Allahham et al.
International journal of pharmaceutics, 270(1-2), 139-148 (2004-01-17)
A micro-capillary rheometer consisted of a fine needle with an internal diameter of 347 microm attached to a 1 ml removable-needle syringe within an Instron device that operated in compression mode to provide various crosshead speeds ranging from 150 to
George Bartzokis et al.
Schizophrenia research, 93(1-3), 13-22 (2007-04-05)
Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination even in adulthood. Atypical antipsychotics have been shown to have a wide spectrum of efficacy across multiple psychiatric diseases and
Zana Stanković et al.
Psychiatria Danubina, 20(1), 42-52 (2008-04-01)
To compare patient's attitudes, demographic, clinical characteristics, psychopathology, insight and type of antipsychotic therapy in compliant and non-compliant outpatients with schizophrenia; to explore correlations between patient's attitudes and related variables. A sample of 44 outpatients of both genders (> 60
Martin Turner et al.
International clinical psychopharmacology, 19(4), 241-249 (2004-06-18)
Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone. Participants in this open-label, multicentre, 12-week trial had received flupenthixol decanoate, fluphenazine decanoate, haloperidol decanoate, or
Who receives long-acting antipsychotic medications?
William M Glazer
Psychiatric services (Washington, D.C.), 58(4), 437-437 (2007-04-07)
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico